D.E. Shaw & Co’s Agios Pharmaceuticals AGIO Stock Holding History

D.E. Shaw & Co’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,000	Closed	-$873K	–	5303
2022 Q1	$873K	Hold	30,000	–	–	﹤0.01%	4022
2021 Q4	$986K	Buy	+30,000	New	+$1.21M	﹤0.01%	3936
2020 Q2	–	Sell	-105,800	Closed	-$3.75M	–	3960
2020 Q1	$3.75M	Buy	105,800 +25,800	+32%	+$1.19M	0.01%	1674
2019 Q4	$3.82M	Buy	80,000 +10,000	+14%	+$378K	﹤0.01%	1947
2019 Q3	$2.27M	Buy	+70,000	New	+$2.9M	﹤0.01%	2255
2019 Q2	–	Sell	-15,000	Closed	-$1.01M	–	3641
2019 Q1	$1.01M	Hold	15,000	–	–	﹤0.01%	2603
2018 Q4	$692K	Buy	+15,000	New	+$926K	﹤0.01%	2898
2015 Q2	–	Sell	-10,000	Closed	-$943K	–	3725
2015 Q1	$943K	Hold	10,000	–	–	﹤0.01%	2600
2014 Q4	$1.12M	Buy	+10,000	New	+$893K	﹤0.01%	2746

Other funds holding AGIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

D.E. Shaw & Co's AGIO Position: Q1 2026 in Review

D.E. Shaw & Co increased its Agios Pharmaceuticals (AGIO) stake by 46% in Q1 2026, buying an estimated $23.9M and bringing the position to 2,681,169 shares worth $90.7M. The position accounts for 0.05% of the portfolio, ranked #415.

D.E. Shaw & Co first reported a position in AGIO in Q2 2014 and has held it in 40 quarters since. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

D.E. Shaw & Co held 2,681,169 shares of Agios Pharmaceuticals worth $90.7M as of Q1 2026.
D.E. Shaw & Co bought 843,983 Agios Pharmaceuticals shares in Q1 2026, an estimated $23.9M.
Agios Pharmaceuticals made up 0.05% of D.E. Shaw & Co's portfolio in Q1 2026, its #415 holding.
D.E. Shaw & Co first reported a position in Agios Pharmaceuticals in Q2 2014 and has held it in 40 quarters since.
232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.